Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-23-055178
Filing Date
2023-03-01
Accepted
2023-03-01 07:50:06
Documents
16
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d469721d10ka.htm   iXBRL 10-K/A 42661
2 EX-31.1 d469721dex311.htm EX-31.1 5164
3 EX-31.2 d469721dex312.htm EX-31.2 10678
  Complete submission text file 0001193125-23-055178.txt   250626

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ngm-20221231.xsd EX-101.SCH 4949
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ngm-20221231_cal.xml EX-101.CAL 656
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ngm-20221231_def.xml EX-101.DEF 1661
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20221231_lab.xml EX-101.LAB 21728
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20221231_pre.xml EX-101.PRE 17230
10 EXTRACTED XBRL INSTANCE DOCUMENT d469721d10ka_htm.xml XML 7481
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38853 | Film No.: 23689820
SIC: 2834 Pharmaceutical Preparations